Anne Green
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anne Green has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
D A Kelly
D A Kelly, Professor in Paediatric Hepatology, The Liver Unit, Birmingham Children's Hospital NHS Trust, UK
1 shared publicationGuidelines Development Group
1 shared publicationJ E Powell
Department of Public Health and Epidemiology, University of Birmingham, UK
1 shared publicationJean Kirk
Department of Paediatric Biochemistry, Royal Hospital for Sick Children, Sciennes Road, Edinburgh EH9 1LF, UK
1 shared publicationS Keffler
S Keffler, formerly Principal Biochemist, Department of Clinical Chemistry, Birmingham Children's Hospital NHS Trust, UK
1 shared publication
Latest Publications
- 1 January 2007
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 44 (1) , 20-24
The sweat test for the diagnosis of cystic fibrosis - a personal experience of guideline production
The need for evidence-based guidelines as to how to conduct the sweat test in the UK was highlighted in 2000 by the National External Quality Assessment Scheme Specialist Advisory Committee. A Guideline Group supported by several professional bodies was subsequently convened and formal evidence-based guidelines were produced and published in 2003. The process of undertaking guideline production is summarized here, together with the author's personal opinions about the experience and highlights of the shortcomings and lessons learnt from the project. In summary, production of evidence-based guidelines is a long process and is only worth the effort (both man hours and financial) if the recommendations are subsequently adopted into clinical practice and in turn improve patient care. The emphasis for the future should be to assess the impact and value of evidence-based guidelines and promote their introduction into local practice as part of care pathways. A growing number of guideline initiatives emphasizes the importance of and a need for an overarching coordinating structure to overcome problems of duplication and enable interested professionals from different disciplines to work on related initiatives.
- 1 January 2007
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 44 (1) , 20-24
The sweat test for the diagnosis of cystic fibrosis - a personal experience of guideline production
The need for evidence-based guidelines as to how to conduct the sweat test in the UK was highlighted in 2000 by the National External Quality Assessment Scheme Specialist Advisory Committee. A Guideline Group supported by several professional bodies was subsequently convened and formal evidence-based guidelines were produced and published in 2003. The process of undertaking guideline production is summarized here, together with the author's personal opinions about the experience and highlights of the shortcomings and lessons learnt from the project. In summary, production of evidence-based guidelines is a long process and is only worth the effort (both man hours and financial) if the recommendations are subsequently adopted into clinical practice and in turn improve patient care. The emphasis for the future should be to assess the impact and value of evidence-based guidelines and promote their introduction into local practice as part of care pathways. A growing number of guideline initiatives emphasizes the importance of and a need for an overarching coordinating structure to overcome problems of duplication and enable interested professionals from different disciplines to work on related initiatives.
- 1 January 2007
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 44 (1) , 25-34
Guidelines for the performance of the sweat test for the diagnosis of cystic fibrosis
A multidisciplinary group (representing various professional bodies and supported by the Cystic Fibrosis Trust) has developed evidence-based guidelines for the performance of the sweat test in the UK. The guidelines cover patient information, subject suitability, sweat collection, sweat analysis, quality, interpretation of results, and responsibility for testing and training. The guidelines were produced following a detailed literature search by the process described by the Royal College of Paediatrics and Child Health (RCPCH), using the Scottish Intercollegiate Guidelines Network 1 (SIGN 1) criteria to grade the evidence. Recommendations are graded A, B, or C, depending on the level of evidence. The grade B recommendations (there were no grade A recommendations) were subsequently appraised and endorsed as part of the RCPCH process, according to Appraisal of Guidelines for Research and Evaluation in Europe (AGREE). The recommendations are summarized in tabular form representing the final version incorporating the comments from the appraisal process. Both the appraisal comments and the full evidence base can be found on www.rcpch.ac.uk/publications/clinical_docs.html. The full guidelines can also be found on http://www.ukneqas.org.uk/guidelines.htm.
- 1 January 2007
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 44 (1) , 25-34
Guidelines for the performance of the sweat test for the diagnosis of cystic fibrosis
A multidisciplinary group (representing various professional bodies and supported by the Cystic Fibrosis Trust) has developed evidence-based guidelines for the performance of the sweat test in the UK. The guidelines cover patient information, subject suitability, sweat collection, sweat analysis, quality, interpretation of results, and responsibility for testing and training. The guidelines were produced following a detailed literature search by the process described by the Royal College of Paediatrics and Child Health (RCPCH), using the Scottish Intercollegiate Guidelines Network 1 (SIGN 1) criteria to grade the evidence. Recommendations are graded A, B, or C, depending on the level of evidence. The grade B recommendations (there were no grade A recommendations) were subsequently appraised and endorsed as part of the RCPCH process, according to Appraisal of Guidelines for Research and Evaluation in Europe (AGREE). The recommendations are summarized in tabular form representing the final version incorporating the comments from the appraisal process. Both the appraisal comments and the full evidence base can be found on www.rcpch.ac.uk/publications/clinical_docs.html. The full guidelines can also be found on http://www.ukneqas.org.uk/guidelines.htm.
- Open Access
- 1 September 2003
- Published by SAGE Publications in Journal of Medical Screening
- Vol. 10 (3) , 112-116
Population Screening for Neonatal Liver Disease: Potential for a Community-Based Programme
Objectives: To evaluate a community-based screening programme for detecting neonata/liver disease by the quantitation of conjugated bilirubin in blood. Setting and Methods: Prospective cohort/observational study using spare plasma from routinely collected liquid neonatal screening specimens from babies born in Birmingham over a two-year period. Babies with a conjugated bilirubin above 18 umol/l and comprising more than 20% of the total bilirubin were followed up. A total of 27,654 neonates were tested in the community, with a further 2425 samples from babies hospitalised at the time of the test. Results: In the community-based series, 84.7% of the specimens received were analysed, the remainder being unusable mainly because of gross hoemolysis (8.6%) or insufficient sample (5.8%). In 107 neonates the results were above the cut-off limits (0.46% of the number analysed). Of these, 12 had persistently abnormal results, 11 of whom hod confirmed liver disease. The liver diseases detected included neonatal hepatitis (n=6), extra-hepatic biliary atresia (n=2), hypopituitarism In= 1), a-1antitrypsin deficiency (n=1) and Alagille syndrome (n= 1). The sensitivity and specificity of the test for babies in the community were 100% and 99.6%, respectively. Conclusions: Conjugated bilirubin in plasma measured at 6–10 days is a reliable marker for neonatal liver disease, and a population screening programme based on this method has the potential to improve the survival and quality of life of infants born with liver disease. However, testing as part of the neonatal screening programme will prove practical only iF the method can be adapted to use dried blood spots
- 1 September 2003
- Published by SAGE Publications in Journal of Medical Screening
- Vol. 10 (3) , 112-116
Open AccessPopulation Screening for Neonatal Liver Disease: Potential for a Community-Based Programme
Objectives: To evaluate a community-based screening programme for detecting neonata/liver disease by the quantitation of conjugated bilirubin in blood. Setting and Methods: Prospective cohort/observational study using spare plasma from routinely collected liquid neonatal screening specimens from babies born in Birmingham over a two-year period. Babies with a conjugated bilirubin above 18 umol/l and comprising more than 20% of the total bilirubin were followed up. A total of 27,654 neonates were tested in the community, with a further 2425 samples from babies hospitalised at the time of the test. Results: In the community-based series, 84.7% of the specimens received were analysed, the remainder being unusable mainly because of gross hoemolysis (8.6%) or insufficient sample (5.8%). In 107 neonates the results were above the cut-off limits (0.46% of the number analysed). Of these, 12 had persistently abnormal results, 11 of whom hod confirmed liver disease. The liver diseases detected included neonatal hepatitis (n=6), extra-hepatic biliary atresia (n=2), hypopituitarism In= 1), a-1antitrypsin deficiency (n=1) and Alagille syndrome (n= 1). The sensitivity and specificity of the test for babies in the community were 100% and 99.6%, respectively. Conclusions: Conjugated bilirubin in plasma measured at 6–10 days is a reliable marker for neonatal liver disease, and a population screening programme based on this method has the potential to improve the survival and quality of life of infants born with liver disease. However, testing as part of the neonatal screening programme will prove practical only iF the method can be adapted to use dried blood spots